Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1870 1
1909 1
1924 1
1946 1
1950 1
1953 1
1955 1
1960 1
1962 1
1963 2
1964 1
1965 2
1966 1
1968 1
1969 3
1970 5
1971 2
1972 9
1973 1
1974 6
1975 4
1976 10
1977 7
1978 8
1979 2
1980 4
1981 5
1982 6
1983 8
1984 10
1985 6
1986 9
1987 11
1988 11
1989 18
1990 12
1991 8
1992 9
1993 13
1994 15
1995 9
1996 11
1997 8
1998 17
1999 7
2000 9
2001 11
2002 11
2003 10
2004 10
2005 15
2006 9
2007 13
2008 13
2009 17
2010 24
2011 28
2012 24
2013 26
2014 19
2015 20
2016 30
2017 40
2018 26
2019 40
2020 27
2021 43
2022 37
2023 41
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

767 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial.
Tesfaye S, Sloan G, Petrie J, White D, Bradburn M, Julious S, Rajbhandari S, Sharma S, Rayman G, Gouni R, Alam U, Cooper C, Loban A, Sutherland K, Glover R, Waterhouse S, Turton E, Horspool M, Gandhi R, Maguire D, Jude EB, Ahmed SH, Vas P, Hariman C, McDougall C, Devers M, Tsatlidis V, Johnson M, Rice ASC, Bouhassira D, Bennett DL, Selvarajah D; OPTION-DM trial group. Tesfaye S, et al. Among authors: petrie j. Lancet. 2022 Aug 27;400(10353):680-690. doi: 10.1016/S0140-6736(22)01472-6. Epub 2022 Aug 22. Lancet. 2022. PMID: 36007534 Free PMC article. Clinical Trial.
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
Araujo D, Greystoke A, Bates S, Bayle A, Calvo E, Castelo-Branco L, de Bono J, Drilon A, Garralda E, Ivy P, Kholmanskikh O, Melero I, Pentheroudakis G, Petrie J, Plummer R, Ponce S, Postel-Vinay S, Siu L, Spreafico A, Stathis A, Steeghs N, Yap C, Yap TA, Ratain M, Seymour L. Araujo D, et al. Among authors: petrie j. Ann Oncol. 2023 Jan;34(1):48-60. doi: 10.1016/j.annonc.2022.09.158. Epub 2022 Sep 29. Ann Oncol. 2023. PMID: 36182023 Free article. Review.
Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review.
Montalban X, Matthews PM, Simpson A, Petrie JL, Sammon C, Ramagopalan S, Disanto G, Kuhle J. Montalban X, et al. Among authors: petrie jl. Ann Clin Transl Neurol. 2023 Mar;10(3):302-311. doi: 10.1002/acn3.51732. Epub 2023 Feb 2. Ann Clin Transl Neurol. 2023. PMID: 36728340 Free PMC article. Review.
Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study.
Wang H, Cordiner RLM, Huang Y, Donnelly L, Hapca S, Collier A, McKnight J, Kennon B, Gibb F, McKeigue P, Wild SH, Colhoun H, Chalmers J, Petrie J, Sattar N, MacDonald T, McCrimmon RJ, Morales DR, Pearson ER; Scottish Diabetes Research Network Epidemiology Group. Wang H, et al. Among authors: petrie j. Diabetes Care. 2023 May 1;46(5):967-977. doi: 10.2337/dc22-1238. Diabetes Care. 2023. PMID: 36944118 Free PMC article. Clinical Trial.
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, Berry C, Chong V, Coyle L, Docherty KF, Dreisbach JG, Labinjoh C, Lang NN, Lennie V, McConnachie A, Murphy CL, Petrie CJ, Petrie JR, Speirits IA, Sourbron S, Welsh P, Woodward R, Radjenovic A, Mark PB, McMurray JJV, Jhund PS, Petrie MC, Sattar N. Lee MMY, et al. Among authors: petrie jr. Circulation. 2021 Feb 9;143(6):516-525. doi: 10.1161/CIRCULATIONAHA.120.052186. Epub 2020 Nov 13. Circulation. 2021. PMID: 33186500 Free PMC article. Clinical Trial.
Optimal pharmacotherapy pathway in adults with diabetic peripheral neuropathic pain: the OPTION-DM RCT.
Tesfaye S, Sloan G, Petrie J, White D, Bradburn M, Young T, Rajbhandari S, Sharma S, Rayman G, Gouni R, Alam U, Julious SA, Cooper C, Loban A, Sutherland K, Glover R, Waterhouse S, Turton E, Horspool M, Gandhi R, Maguire D, Jude E, Ahmed SH, Vas P, Hariman C, McDougall C, Devers M, Tsatlidis V, Johnson M, Bouhassira D, Bennett DL, Selvarajah D. Tesfaye S, et al. Among authors: petrie j. Health Technol Assess. 2022 Oct;26(39):1-100. doi: 10.3310/RXUO6757. Health Technol Assess. 2022. PMID: 36259684 Free PMC article. Clinical Trial.
A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
Nauck MA, Petrie JR, Sesti G, Mannucci E, Courrèges JP, Lindegaard ML, Jensen CB, Atkin SL; Study 1821 Investigators. Nauck MA, et al. Among authors: petrie jr. Diabetes Care. 2016 Feb;39(2):231-41. doi: 10.2337/dc15-0165. Epub 2015 Sep 10. Diabetes Care. 2016. PMID: 26358288 Clinical Trial.
Health Care-Acquired Viral Respiratory Diseases.
Petrie JG, Talbot TR. Petrie JG, et al. Infect Dis Clin North Am. 2021 Dec;35(4):1055-1075. doi: 10.1016/j.idc.2021.07.007. Infect Dis Clin North Am. 2021. PMID: 34752220 Free PMC article. Review.
Recent developments in adjunct therapies for type 1 diabetes.
Timmons JG, Littlejohn L, Boyle JG, Petrie JR. Timmons JG, et al. Among authors: petrie jr. Expert Opin Investig Drugs. 2022 Dec;31(12):1311-1320. doi: 10.1080/13543784.2022.2159806. Epub 2023 Jan 26. Expert Opin Investig Drugs. 2022. PMID: 36655950 Review.
767 results